Domingo Francisco Javier Dez Martnez

List of Publications by Citations

287 papers	14,739 citations	71 h-index	110 g-index
326 ext. papers	17,220 ext. citations	5.6 avg, IF	6.47 L-index

#	Paper	IF	Citations
287	Myocardial remodeling after infarction: the role of myofibroblasts. *Nature Reviews Cardiology*, **2010**, 7, 30-7	14.8	502
286	Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. *Circulation*, **2002**, 105, 2512-7	16.7	489
285	Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2010**, 363, 552-63	59.2	452
284	Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. *Circulation*, **2004**, 110, 1263-8	16.7	320
283	Prevalence of left ventricular diastolic dysfunction in a general population. *Circulation: Heart Failure*, **2009**, 2, 105-12	7.6	233
282	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *European Heart Journal*, **2014**, 35, 2797-815	9.5	231
281	Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. *Circulation*, **2001**, 104, 286-91	16.7	214
280	Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. *Journal of the American College of Cardiology*, **2018**, 71, 1696-1706	15.1	204
279	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. *Journal of the American College of Cardiology*, **2004**, 43, 2028-35	15.1	204
278	Myocardial fibrosis: biomedical research from bench to bedside. *European Journal of Heart Failure*, **2017**, 19, 177-191	12.3	195
277	Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. *Journal of the American College of Cardiology*, **2006**, 48, 89-96	15.1	184
276	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. *Circulation: Heart Failure*, **2013**, 6, 1239-49	7.6	183
275	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H1-9	5.2	177
274	Torasemide in chronic heart failure: results of the TORIC study. *European Journal of Heart Failure*, **2002**, 4, 507-13	12.3	169
273	Circulating biomarkers of collagen metabolism in cardiac diseases. *Circulation*, **2010**, 121, 1645-54	16.7	168
272	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. *American Journal of Cardiology*, **2001**, 88, 1L-20L	3	164
271	T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. *Circulation: Cardiovascular Imaging*, **2013**, 6, 415-22	3.9	158

270	Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. *Journal of the American College of Cardiology*, **2018**, 71, 860-871	15.1	152
269	Mechanisms of cardiac fibrosis in hypertension. *Journal of Clinical Hypertension*, **2007**, 9, 546-50	2.3	149
268	C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. *Journal of the American College of Cardiology*, **2006**, 47, 1369-78	15.1	147
267	Surrogate markers for cardiovascular disease: structural markers. *Circulation*, **2004**, 109, IV22-30	16.7	146
266	Biochemical assessment of myocardial fibrosis in hypertensive heart disease. *Hypertension*, **2001**, 38, 1222-6	8.5	143
265	Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. *Hepatology*, **1994**, 19, 1400-1406	11.2	142
264	Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. *Circulation*, **2004**, 110, 552-7	16.7	135
263	Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. *Journal of the American College of Cardiology*, **2015**, 65, 2449-56	15.1	132
262	New targets to treat the structural remodeling of the myocardium. *Journal of the American College of Cardiology*, **2011**, 58, 1833-43	15.1	129
261	Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. *Hypertension*, **2009**, 53, 236-42	8.5	120
260	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. *Journal of the American Heart Association*, **2015**, 4,	6	119
259	Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. *Hypertension*, **2012**, 60, 677-83	8.5	118
258	Abnormal expression of anion exchanger genes in primary biliary cirrhosis. *Gastroenterology*, **1993**, 105, 572-8	13.3	118
257	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. *Nature Communications* , **2016**, 7, 13710	17.4	118
256	Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 209-16		116
255	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. *European Heart Journal*, **2018**, 39, 699-709	9.5	112
254	Oxidative stress and vascular remodelling. *Experimental Physiology*, **2005**, 90, 457-62	2.4	108
253	Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. *Nephrology Dialysis Transplantation*, **2001**, 16 Suppl 1, 14-7	4.3	108

252	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. *JAMA Cardiology*, **2017**, 2, 995-1006	16.2	107
251	Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. *Diabetes*, **2006**, 55, 209-15	0.9	106
250	Clinical aspects of hypertensive myocardial fibrosis. *Current Opinion in Cardiology*, **2001**, 16, 328-35	2.1	106
249	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere´mutation carriers: a pilot randomized trial to modify disease expression. *JACC: Heart Failure*, **2015**, 3, 180-8	7.9	105
248	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. *Endocrinology*, **2007**, 148, 324-31	4.8	100
247	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. *European Journal of Heart Failure*, **2019**, 21, 272-285	12.3	99
246	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. *Cardiovascular Drugs and Therapy*, **2002**, 16, 149-60	3.9	96
245	Vascular oxidant stress: molecular mechanisms and pathophysiological implications. *Journal of Physiology and Biochemistry*, **2000**, 56, 57-64	5	95
244	Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. *Journal of the American College of Cardiology*, **2007**, 50, 859-67	15.1	93
243	Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. *Journal of Molecular and Cellular Cardiology*, **2002**, 34, 1585-93	5.8	93
242	Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. *Journal of Hypertension*, **1999**, 17, 107-14	1.9	92
241	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. *Hypertension*, **2018**, 71, 280-288	8.5	90
240	Myocardial Collagen Cross-Linking Is´Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. *Journal of the American College of Cardiology*, **2016**, 67, 251-60	15.1	90
239	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. *Journal of Hypertension*, **2002**, 20, 1855-64	1.9	90
238	Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. *Hypertension*, **2010**, 55, 1418-24	8.5	89
237	Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. *Hypertension*, **2002**, 39, 75-80	8.5	89
236	A translational approach to hypertensive heart disease. *Hypertension*, **2010**, 55, 1-8	8.5	85
235	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. *Cardiovascular Research*, **2013**, 99, 111-20	9.9	83

234	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. *Cardiovascular Research*, **2003**, 59, 549-62	9.9	81
233	Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. *Hypertension*, **2004**, 44, 163-9	8.5	80
232	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. *Journal of Hypertension*, **2004**, 22, 2169-75	1.9	80
231	NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. *Antioxidants and Redox Signaling*, **2005**, 7, 1327-36	8.4	80
230	NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. *Clinical Science*, **2008**, 114, 173-82	6.5	78
229	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). *Journal of Hypertension*, **2007**, 25, 1958-66	1.9	78
228	G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. *Diabetes*, **2010**, 59, 2407-17	0.9	77
227	Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. *Endocrinology*, **2002**, 143, 3555-60	4.8	76
226	AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 294, H853-8	5.2	75
225	A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. *Cardiovascular Research*, **2009**, 81, 601-9	9.9	75
224	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. *Journal of Hypertension*, **2006**, 24, 1299-306	1.9	75
223	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β up-regulation. *Clinical Science*, **2014**, 126, 497-506	6.5	74
222	GLP-1 and cardioprotection: from bench to bedside. *Cardiovascular Research*, **2012**, 94, 316-23	9.9	74
221	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. *Medical Clinics of North America*, **2004**, 88, 83-97	7	74
220	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. *European Journal of Heart Failure*, **2015**, 17, 764-71	12.3	73
219	Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. *FEBS Letters*, **2003**, 542, 27-31	3.8	73
218	Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 587-93	9.4	71
217	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. *Biomaterials*, **2014**, 35, 143-51	15.6	68

216	Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H1361-72	5.2	65
215	Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. *Hypertension*, **2002**, 39, 923-8	8.5	63
214	Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. *European Journal of Heart Failure*, **2017**, 19, 167-176	12.3	62
213	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 290, H1503-9	5.2	62
212	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 294, E52-60	6	60
211	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. *Journal of Hypertension*, **2005**, 23, 625-32	1.9	60
210	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. *Journal of Hypertension*, **2001**, 19, 1871-6	1.9	60
209	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. *Cardiovascular Ultrasound*, **2012**, 10, 10	2.4	58
208	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. *Journal of Hypertension*, **2005**, 23, 1445-51	1.9	58
207	NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1452-7	9.4	58
206	Myocardial Remodeling in Hypertension. *Hypertension*, **2018**, 72, 549-558	8.5	58
205	Biochemical markers of myocardial remodelling in hypertensive heart disease. *Cardiovascular Research*, **2009**, 81, 509-18	9.9	57
204	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. *Journal of Hypertension*, **2011**, 29, 17-26	1.9	55
203	Arterial stiffness and extracellular matrix. *Advances in Cardiology*, **2007**, 44, 76-95		55
202	Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. *Hypertension*, **2009**, 54, 744-50	8.5	54
201	Oxidative stress, endothelial dysfunction and cerebrovascular disease. *Cerebrovascular Diseases*, **2007**, 24 Suppl 1, 24-9	3.2	54
200	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. *Journal of the American College of Cardiology*, **2019**, 73, 1795-1806	15.1	52
199	Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. *Hypertension*, **2012**, 60, 563-73	8.5	52

198	Sex Dimorphism in the Myocardial Response to Aortic Stenosis. *JACC: Cardiovascular Imaging*, **2018**, 11, 962-973	8.4	51
197	Oxidative stress and atherosclerosis in early chronic kidney disease. *Nephrology Dialysis Transplantation*, **2006**, 21, 2686-90	4.3	50
196	Apoptosis in hypertensive heart disease. *Current Opinion in Cardiology*, **1998**, 13, 317-25	2.1	50
195	Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. *Hypertension*, **2000**, 36, 1065-71	8.5	49
194	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H2372-82	5.2	48
193	Association between left ventricular mass and telomere length in a population study. *American Journal of Epidemiology*, **2010**, 172, 440-50	3.8	46
192	Telomere dysfunction in hypertension. *Journal of Hypertension*, **2007**, 25, 2185-92	1.9	46
191	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. *Hypertension*, **2019**, 73, 602-611	8.5	44
190	Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. *European Journal of Heart Failure*, **2018**, 20, 1290-1299	12.3	42
189	Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. *Cytokine*, **2005**, 30, 282-92	4	42
188	Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. *Journal of Molecular and Cellular Cardiology*, **2006**, 41, 902-13	5.8	41
187	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. *Cardiovascular Research*, **2009**, 83, 586-94	9.9	40
186	Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 2187-94	9.4	40
185	Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. *Hypertension*, **2007**, 50, 977-83	8.5	40
184	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. *Journal of Hypertension*, **2007**, 25, 2148-57	1.9	40
183	The loop diuretic torasemide interferes with endothelin-1 actions in the aorta of hypertensive rats. *Nephrology Dialysis Transplantation*, **2001**, 16 Suppl 1, 18-21	4.3	40
182	Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. *American Journal of Hypertension*, **1995**, 8, 815-22	2.3	40
181	Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. *European Journal of Heart Failure*, **2015**, 17, 385-92	12.3	39

180	Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. *Hypertension*, **2014**, 63, 483-9	8.5	39
179	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. *Journal of Hypertension*, **2009**, 27, 418-24	1.9	39
178	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. *Nephrology Dialysis Transplantation*, **2001**, 16 Suppl 1, 2-5	4.3	39
177	Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. *Endocrinology*, **2008**, 149, 4970-8	4.8	38
176	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. *Cardiovascular Research*, **2006**, 69, 899-907	9.9	38
175	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. *Kidney International*, **2005**, S71-5	9.9	38
174	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. *Journal of Hypertension*, **2005**, 23, 2297-304	1.9	36
173	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. *Journal of the American College of Cardiology*, **2019**, 73, 1016-1025	15.1	35
172	Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. *Hypertension*, **2013**, 61, 120-9	8.5	35
171	Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. *American Journal of Hypertension*, **1994**, 7, 52-8	2.3	35
170	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. *Current Opinion in Nephrology and Hypertension*, **2004**, 13, 197-204	3.5	34
169	Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. *European Heart Journal*, **2005**, 26, 153-8	9.5	34
168	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. *Circulation: Heart Failure*, **2019**, 12, e005897	7.6	33
167	Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. *Journal of the American College of Cardiology*, **2019**, 73, 1398-1410	15.1	33
166	Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 2448-56	6.9	33
165	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. *Free Radical Biology and Medicine*, **2009**, 46, 1058-67	7.8	33
164	Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. *Kidney International*, **2008**, S19-23	9.9	33
163	Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. *Journal of Hypertension*, **2010**, 28, 1944-50	1.9	32

162	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. *Journal of Hypertension*, **2006**, 24, 1589-97	1.9	32
161	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. *Kidney International*, **2010**, 78, 1275-80	9.9	31
160	Towards a new paradigm about hypertensive heart disease. *Medical Clinics of North America*, **2009**, 93, 637-45	7	31
159	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. *Cardiovascular Research*, **2011**, 92, 247-55	9.9	31
158	A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension. *Journal of Hypertension*, **2007**, 25, 1620-6	1.9	31
157	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. *Scientific Reports*, **2017**, 7, 40696	4.9	30
156	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. *Journal of Hypertension*, **2017**, 35, 853-861	1.9	30
155	The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2319-27	5.6	30
154	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2019**, 1866, 1421-1432	4.9	29
153	"Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. *JACC: Heart Failure*, **2015**, 3, 661-9	7.9	28
152	Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?. *Cardiovascular Research*, **2007**, 75, 536-45	9.9	28
151	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. *Journal of the American Heart Association*, **2017**, 6,	6	27
150	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. *Hypertension*, **2019**, 73, 820-828	8.5	27
149	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. *Circulation*, **2020**, 141, 751-767	16.7	27
148	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. *European Heart Journal*, **2007**, 28, 2785-91	9.5	27
147	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. *Clinical Therapeutics*, **2006**, 28, 832-48	3.5	26
146	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. *Matrix Biology*, **2018**, 66, 110-124	11.4	25
145	Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. *European Heart Journal*, **2008**, 29, 898-906	9.5	25

144	Vascular effects of cardiotrophin-1: a role in hypertension?. *Journal of Hypertension*, **2010**, 28, 1261-72	1.9	25
143	Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. *FASEB Journal*, **2018**, 32, fj201701408R	0.9	24
142	Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions. *American Journal of Cardiovascular Drugs*, **2014**, 14, 275-85	4	24
141	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. *Cardiovascular Diabetology*, **2013**, 12, 143	8.7	24
140	Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects. *Cerebrovascular Diseases*, **2003**, 16, 356-62	3.2	24
139	Ultrasonic backscatter and diastolic function in hypertensive patients. *Hypertension*, **2002**, 40, 239-43	8.5	24
138	Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. *Cardiovascular Research*, **2010**, 88, 304-13	9.9	23
137	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. *European Heart Journal*, **2021**, 42, 684-696	9.5	23
136	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. *Journal of Hypertension*, **2016**, 34, 130-8	1.9	23
135	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. *Journal of Cardiovascular Medicine*, **2014**, 15, 463-9	1.9	22
134	Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension. *American Journal of Hypertension*, **1997**, 10, 84-93	2.3	22
133	Apoptosis in hypertensive heart disease: a clinical approach. *Current Opinion in Cardiology*, **2006**, 21, 288-94	2.1	22
132	Insulin-like growth factor I in essential hypertension. *Kidney International*, **1999**, 55, 744-59	9.9	22
131	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. *International Journal of Cardiology*, **2015**, 185, 177-85	3.2	21
130	Papel del colágeno miocárdico en la estenosis aórtica grave con fracción de eyección conservada y síntomas de insuficiencia cardiaca. *Revista Espanola De Cardiologia*, **2017**, 70, 832-840	1.5	20
129	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study. *Free Radical Biology and Medicine*, **2015**, 81, 1-12	7.8	20
128	Cardiotrophin-1 in hypertensive heart disease. *Endocrine*, **2012**, 42, 9-17	4	20
127	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. *Nature Reviews Cardiology*, **2021**, 18, 479-498	14.8	20

126	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. *European Heart Journal*, **2018**, 39, 2793-2799	9.5	19
125	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. *Scientific Reports*, **2017**, 7, 16042	4.9	19
124	Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes. *Cardiovascular Research*, **2012**, 96, 81-9	9.9	19
123	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. *PLoS ONE*, **2016**, 11, e0167582	3.7	19
122	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar. *Journal of the American College of Cardiology*, **2020**, 75, 2204-2218	15.1	18
121	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. *Heart*, **2019**, 105, 307-314	5.1	18
120	Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. *Journal of Hypertension*, **2006**, 24, 395-402	1.9	18
119	Peroxisome proliferator-activated receptor alpha and hypertensive heart disease. *Drugs*, **2004**, 64 Suppl 2, 9-18	12.1	18
118	Effects of antihypertensive agents on the left ventricle: clinical implications. *American Journal of Cardiovascular Drugs*, **2001**, 1, 263-79	4	18
117	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. *Scientific Reports*, **2017**, 7, 41865	4.9	17
116	Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins. *Cardiovascular Research*, **2010**, 87, 591-2	9.9	17
115	Profibrotic effects of angiotensin II in the heart: a matter of mediators. *Hypertension*, **2004**, 43, 1164-5	8.5	17
114	Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2020**, 76, 735-744	15.1	17
113	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. *Free Radical Research*, **2017**, 51, 389-396	4	16
112	A Urinary Fragment of Mucin-1 Subunit is a Novel Biomarker Associated With Renal Dysfunction in the General Population. *Kidney International Reports*, **2017**, 2, 811-820	4.1	16
111	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients 60 Years With Heart Failure and Reduced Ejection Fraction. *American Journal of Cardiology*, **2017**, 119, 2042-2048	3	16
110	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). *European Journal of Heart Failure*, **2018**, 20, 460-470	12.3	16
109	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. *European Heart Journal*, **2011**, 32, 177-83	9.5	16

108	Diagnosis and treatment of myocardial fibrosis in hypertensive heart disease. *Circulation Journal*, **2008**, 72 Suppl A, A8-12	2.9	16
107	Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. *Journal of Biomedical Research*, **2014**, 28, 349-59	1.5	16
106	Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure. *Circulation: Heart Failure*, **2016**, 9,	7.6	16
105	Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2016**, 2, 119-30	6.4	15
104	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. *Open Heart*, **2017**, 4, e000615	3	15
103	Effects of aldosterone on the heart: beyond systemic hemodynamics?. *Hypertension*, **2008**, 52, 462-4	8.5	15
102	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. *ESC Heart Failure*, **2018**, 5, 139-148	3.7	14
101	Arterial hypertension in patients with heart failure. *Heart Failure Clinics*, **2014**, 10, 233-42	3.3	14
100	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. *Scandinavian Cardiovascular Journal*, **2014**, 48, 299-303	2	14
99	A synthetic peptide from transforming growth factor-□type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats. *Antioxidants and Redox Signaling*, **2013**, 19, 1607-18	8.4	14
98	The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes. *Medical Clinics of North America*, **2017**, 101, 43-52	7	14
97	Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1?. *Hypertension*, **2014**, 63, 468-74	8.5	14
96	Blockade of TGF-□1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. *Oxidative Medicine and Cellular Longevity*, **2012**, 2012, 726940	6.7	14
95	A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. *Journal of the American College of Cardiology*, **2006**, 47, 2335-7	15.1	14
94	Urinary peptides in heart failure: a link to molecular pathophysiology. *European Journal of Heart Failure*, **2021**, 23, 1875-1887	12.3	14
93	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. *Cardiovascular Research*, **2017**, 113, 906-914	9.9	13
92	Enhanced Na(+)-H+ exchanger activity and NHE-1 mRNA expression in lymphocytes from patients with essential hypertension. *Hypertension*, **1995**, 25, 356-64	8.5	13
91	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. *JACC: Heart Failure* , **2021**, 9, 268-277	7.9	13

90	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 832-840	0.7	12
89	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. *Journal of Hypertension*, **2013**, 31, 587-94	1.9	12
88	TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. *Expert Review of Cardiovascular Therapy*, **2009**, 7, 897-904	2.5	12
87	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. *Journal of Hypertension*, **2009**, 27, 1420-30	1.9	12
86	Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats. *American Journal of Hypertension*, **1997**, 10, 1147-52	2.3	12
85	New directions in the assessment and treatment of hypertensive heart disease. *Current Opinion in Nephrology and Hypertension*, **2005**, 14, 428-34	3.5	12
84	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. *Journal of Hypertension*, **1998**, 16, 863-70	1.9	12
83	Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. *American Journal of Cardiology*, **1995**, 76, 14D-17D	3	12
82	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. *Journal of Hypertension*, **1997**, 15, 1159-65	1.9	11
81	Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. *European Journal of Clinical Investigation*, **2002**, 32, 291-4	4.6	11
80	Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. *Gastroenterology*, **1991**, 101, 1354-60	13.3	11
79	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. *Clinical Research in Cardiology*, **2020**, 109, 22-33	6.1	11
78	Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. *JACC Basic To Translational Science*, **2021**, 6, 12-21	8.7	11
77	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. *Diabetologia*, **2020**, 63, 1043-1054	10.3	10
76	Why Clinicians Should Care About the ́Cardiac Interstitium. *JACC: Cardiovascular Imaging*, **2019**, 12, 2305-2318	8.4	10
75	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. *Clinical Science*, **2013**, 125, 291-300	6.5	10
74	Overexpression of human truncated peroxisome proliferator-activated receptor alpha induces apoptosis in HL-1 cardiomyocytes. *Cardiovascular Research*, **2008**, 79, 458-63	9.9	10
73	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. *Journal of Hypertension*, **2003**, 21, 2085-92	1.9	10

72	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. *Proteomics - Clinical Applications*, **2011**, 5, 222-32	3.1	9
71	Obesity-related cardiac and vascular structural alterations: beyond blood pressure overload. *Journal of Hypertension*, **2009**, 27, 1750-2	1.9	9
70	Intracerebroventricular infusion of sodium chloride-rich artificial cerebrospinal fluid in rats induces natriuresis and releases an inhibitor of prostaglandin synthesis. *Clinical Science*, **1984**, 66, 621-4	6.5	9
69	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. *Clinical Science*, **2016**, 130, 2139-2149	6.5	8
68	Do microRNAs regulate myocardial fibrosis?. *Nature Clinical Practice Cardiovascular Medicine*, **2009**, 6, 88-9		8
67	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. *Clinical Science*, **2009**, 116, 233-40	6.5	8
66	Uremia and red blood cell sodium transport. *Nephron*, **1986**, 43, 155-7	3.3	8
65	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy´´A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. *European Journal of Heart Failure*, **2021**, 23, 933-944	12.3	8
64	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. *Scientific Reports*, **2019**, 9, 2956	4.9	8
63	Epicardial Adipose Tissue in the General Middle-aged Population and Its Association With Metabolic Syndrome. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 254-260	0.7	7
62	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
61	Involvement of cardiomyocyte survival-apoptosis balance in hypertensive cardiac remodeling. *Expert Review of Cardiovascular Therapy*, **2003**, 1, 293-307	2.5	7
60	Glucagon-like peptide 1 and cardiac cell survival. *Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion*, **2012**, 59, 561-9		6
59	The influence of obesity on the assessment of carotid intima-media thickness. *Journal of Clinical Ultrasound*, **2012**, 40, 479-85	1	6
58	Association of the peroxisome proliferator-activated receptor gene L162V polymorphism with stage C heart failure. *Journal of Hypertension*, **2011**, 29, 876-83	1.9	6
57	Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares (RECAVA). *Revista Espanola De Cardiologia*, **2008**, 61, 58-65	1.5	6
56	Asociación de la metaloproteinasa-10 y el tabaquismo en sujetos sin enfermedad cardiovascular. *Revista Espanola De Cardiologia*, **2008**, 61, 1267-1273	1.5	6
55	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. *Clinical Chemistry and Laboratory Medicine*, **2004**, 42, 384-6	5.9	6

54	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. *Nefrologia*, **2020**, 40, 223-236	1.5	6
53	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. *Diabetes Care*, **2021**, 44, 224-230	14.6	6
52	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study. *Journal of Cardiovascular Electrophysiology*, **2019**, 30, 1231-1240	2.7	5
51	Targeting □secretases protect against angiotensin II-induced cardiac hypertrophy. *Journal of Hypertension*, **2015**, 33, 843-50; discussion 850	1.9	5
50	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. *Journal of Hypertension*, **2010**, 28, 2219-26	1.9	5
49	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. *Current Hypertension Reviews*, **2007**, 3, 1-7	2.3	5
48	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. *Frontiers in Bioscience - Elite*, **2011**, 3, 1467-74	1.6	5
47	Reprint of "The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking". *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118521	4.9	5
46	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. *European Heart Journal*, **2019**, 40, 979-981	9.5	4
45	Vasodilator effect of ghrelin in the rat aorta. *Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion*, **2008**, 55, 448-53		4
44	Angiotensin II and the hypertensive heart: a role for the AT2 receptor?. *Journal of Hypertension*, **2004**, 22, 879-82	1.9	4
43	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. *Revista Espanola De Cardiologia*, **2020**, 73, 248-254	1.5	4
42	Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. *Journal of Hypertension*, **2020**, 38, 2036-2042	1.9	4
41	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. *Revista Espanola De Cardiologia (English Ed)*, **2020**, 73, 835-843	0.7	3
40	Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. *Kidney International*, **1998**, 68, S10-3	9.9	3
39	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 754499	5.4	3
38	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. *Revista Espanola De Cardiologia (English Ed)*, **2020**, 73, 248-254	0.7	3
37	Bases para la creación de las unidades clínicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. *REC: CardioClinics*, **2021**, 56, 284-284	0.2	3

36	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. *Journal of the American Heart Association*, **2019**, 8, e010430	6	3
35	Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure. *Clinical and Translational Medicine*, **2021**, 11, e267	5.7	3
34	Hypertrophic cardiomyopathy in myosin-binding protein C () Icelandic founder mutation carriers. *Open Heart*, **2020**, 7, e001220	3	2
33	Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. *Revista Espanola De Cardiologia (English Ed)*, **2009**, 62, 305-13	0.7	2
32	Hypertensive Heart Disease **2007**, 621-631		2
31	Current work in the cell biology of left ventricular hypertrophy. *Current Opinion in Cardiology*, **1994**, 9, 512-9	2.1	2
30	Elevated levels of parathyroid hormone in essential hypertensive patients with increased erythrocyte potassium efflux. *American Journal of Hypertension*, **1991**, 4, 714-8	2.3	2
29	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. *European Journal of Heart Failure*, **2021**,	12.3	2
28	Left Ventricular Hypertrophy and Treatment with Renin Angiotensin System Inhibition **2009**, 103-119		2
27	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. *Nefrologia*, **2020**, 40, 223-236	0.4	2
26	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. *American Journal of Hypertension*, **2019**, 32, 15-17	2.3	2
25	Management of cardiac fibrosis is the largest unmet medical need in heart failure Cardiac fibrosis in heart failure. *Cardiovascular Research*, **2021**,	9.9	2
24	Hypertensive heart disease **2013**, 152-166		1
23	Towards the molecular diagnosis of hypertensive heart disease?. *Journal of Hypertension*, **2011**, 29, 660-2	4.9	1
22	Cooperative Cardiovascular Disease Research Network (RECAVA). *Revista Espanola De Cardiologia (English Ed)*, **2008**, 61, 58-65	0.7	1
21	Heart failure-related skeletal myopathy. Potential involvement of myokines. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 74, 1008-1012	0.7	1
20	Identification of sex-specific biomarkers predicting new-onset heart failure. *ESC Heart Failure*, **2021**, 8, 3512-3520	3.7	1
19	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. *Nefrologia*, **2021**, 41, 391-402	1.5	1

18	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. *Journal of Cardiovascular Pharmacology*, **2021**, 78, e703-e713	3.1	1
17	Renin–Angiotensin–Aldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease **2009**, 143-150		1
16	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 865-872	4.5	1
15	Corrigendum to "Torasemide in chronic heart failure: results of the TORIC study" [Eur. J. Heart Fail. 4 (2002) 507–513]. *European Journal of Heart Failure*, **2002**, 4, 667-667	12.3	0
14	Fibrosis miocárdica: hacia una nueva aproximación. *Revista Colombiana De Cardiologia*, **2019**, 26, 142-151	0.1	
13	Biomarkers of Cardiovascular Disease **2019**, 319-330		
12	Aspectos emergentes del sistema renina-angiotensina en la diabetes: ¿cómo abordar su traslación a la clínica?. *Revista Espanola De Cardiologia Suplementos*, **2011**, 11, 37-41	0.2	
11	Angiotensin II and myocardial remodeling: do macrophages hold the key?. *American Journal of Hypertension*, **2011**, 24, 626-7	2.3	
10	Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27–31]. *FEBS Letters*, **2010**, 584, 4709-4709	3.8	
9	Avances en cardiopatía hipertensiva. Mecanismos de remodelado implicados en la transición de la hipertrofia a la insuficiencia cardiaca. *Revista Espanola De Cardiologia Suplementos*, **2007**, 7, 14F-21F	0.2	
8	Serum Markers of Fibrillar Collagen Metabolism in Cardiac Diseases **2005**, 101-113		
7	Highlight from International Congress. *High Blood Pressure and Cardiovascular Prevention*, **2006**, 13, 61-72	2.9	
6	Angiotensin II and Myocardial Fibrosis, Clinical Implications **2006**, 193-213		
5	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. *Nefrologia*, **2021**, 41, 391-402	0.4	
4	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System **2006**, 177-189		
3	Reply: Aortic Stenosis, Left Ventricular Remodeling, and Renin-Angiotensin System Blockade. *Journal of the American College of Cardiology*, **2018**, 71, 2984-2985	15.1	
2	What is on the horizon for improved treatments for acutely decompensated heart failure?. *European Heart Journal Supplements*, **2016**, 18, G33-G42	1.5	
1	Miopatía esquelética en la insuficiencia cardiaca. Implicación potencial de las miocinas. *Revista Espanola De Cardiologia*, **2021**, 74, 1009-1009	1.5	